CXCR4 and cancer: These findings have direct clinical implications, as Zhang et al.’s analysis indicates that cancers enriched with CXCR4+ tip cells may exhibit greater sensitivity to anti-angiogenic therapies, whereas those with abundant SELE+ veins may demonstrate enhanced responsiveness to immune checkpoint inhibitors [43].